课题基金 / 基金详情

Role of METTL3 and the m6A Epitranscriptome in cancer

Role of METTL3 and the m6A Epitranscriptome in cancer
METTL3 和 m6A 表观转录组在癌症中的作用
批准号:
10302284
负责人:
Richard I. Gregory
金额:
$63.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-12-11 至 2024-11-30

项目摘要

项目成果

Richard I. Gregory的其他基金

相似基金

相关文献

中文摘要
翻译
肺腺癌约占所有肺癌的40%,是最常见的肺部疾病。 癌症发生在女性和45岁以下的人群中。令人惊讶的是,肺癌的5年存活率 癌症总体上只有18%左右,超过一半的肺癌患者在一年内死亡 诊断。这突出了对更有效的治疗选择的需要,并强调了 研究的重点是发现和了解有助于 肺癌生物学。信使RNA(MRNAs)受到各种转录后修饰的影响 包括N6-甲基腺苷(M6A)。M6A是最丰富的mRNA修饰,正在作为一种 重要的基因表达调节因子,可影响信使核糖核酸的剪接、输出、稳定性和翻译。M6A 是由METTL3甲基转移酶复合体催化的,出现在一个特征序列基序中 靠近一大部分mRNAs翻译终止密码子的位置。这项提案的目标是测试 认为METTL3是一种新的肺癌致癌因子的中心假说。全球M6A基因的表达 “表位转录组”将在一组原发人类肺癌样本中进行绘制和测量。相对的 用免疫组织化学方法检测肿瘤组织中METTL3的水平,并与M6A水平进行相关分析 以及转录组的广泛分布。功能损失和功能增益实验将解决广泛存在的 METTL3(和METTL3相互作用蛋白)在控制靶mRNA表达中的作用,并将有助于 揭示METTL3、METTL3相互作用蛋白的分子和细胞作用,以及精选的 下游靶向于肺癌细胞生物学中的mRNAs。最后,METTL3手法对肺的影响 肿瘤的发生和发展将使用小鼠肺癌模型和一种新的肺来探索 将部署有机物模型和一组分析来研究潜在的分子机制。 拟议研究的成功完成将有助于将METTL3确立为未来可能的治疗方法 肺腺癌和其他癌症的靶点。
英文摘要
Lung adenocarcinoma accounts for about 40% of all lung cancers and is the most common form of lung cancer found in women and in people under the age of forty-five. Strikingly, the 5-year survival rate for lung cancer overall is only about 18 percent, and more than half of people with lung cancer die within one year of diagnosis. This highlights the need for more effective treatment options and underscores the importance of research focused on uncovering and understanding new molecular and cellular pathways that contribute to lung cancer biology. Messenger RNAs (mRNAs) are subject to various posttranscriptional modifications including N6-Methyladenosine (m6A). m6A is the most abundant mRNA modification and is emerging as an important regulator of gene expression that can affect mRNA splicing, export, stability, and translation. m6A is catalyzed the METTL3 methyltransferase complex, and occurs at a characteristic sequence motif at a position close to the translation stop codon of a large subset of mRNAs. The goal of this proposal is to test the central hypothesis that METTL3 is a novel oncogenic factor in lung cancer. The global m6A mRNA `epitranscriptome' will be mapped and measured in a cohort of primary human lung tumor samples. Relative levels of METTL3 in tumors will be measured by immunohistochemistry and correlated with the m6A levels and transcriptome-wide distribution. Loss- and gain-of-function experiments will address the widespread impact of METTL3 (and METTL3-interacting proteins) in controlling target mRNA expression, and will help uncover the molecular and cellular role of METTL3, METTL3-interacting proteins, and a selection of downstream targets mRNAs, in lung cancer cell biology. Finally, the effects of METTL3 manipulation in lung tumor initiation and progression will be explored using a mouse lung cancer model, as well as a novel lung organoid model and a panel of assays will be deployed to examine the underlying molecular mechanism. Successful completion of the proposed studies will help establish METTL3 as a possible future therapeutic target for lung adenocarcinoma and other cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of the Epitranscriptome in Cancer
  • 批准号:
    10450108
  • 项目类别:
  • 资助金额:
    $104.08万
  • 财政年份:
    2019
  • 负责人:
    Richard I. Gregory
  • 依托单位:
Role of the Epitranscriptome in Cancer
  • 批准号:
    10219192
  • 项目类别:
  • 资助金额:
    $106.2万
  • 财政年份:
    2019
  • 负责人:
    Richard I. Gregory
  • 依托单位:
Role of METTL3 and the m6A Epitranscriptome in cancer
  • 批准号:
    10520012
  • 项目类别:
  • 资助金额:
    $63.06万
  • 财政年份:
    2019
  • 负责人:
    Richard I. Gregory
  • 依托单位:
Role of the Epitranscriptome in Cancer
  • 批准号:
    9979795
  • 项目类别:
  • 资助金额:
    $106.2万
  • 财政年份:
    2019
  • 负责人:
    Richard I. Gregory
  • 依托单位:
海外基金